Results 31 to 40 of about 282,663 (297)

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia

Journal of Hematology & Oncology, 2021
In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2 weeks after the second dose was significantly lower in the ten ...
F. Pimpinelli, F. Marchesi, G. Piaggio, D. Giannarelli, E. Papa, P. Falcucci, A. Spadea, M. Pontone, S. di Martino, V. Laquintana, Antonia Marina La Malfa, E. D. Di Domenico, O. di Bella, Gianluca Falzone, F. Ensoli, B. Vujovic, A. Morrone, G. Ciliberto, A. Mengarelli   +18 more
semanticscholar   +1 more source

In Stent Restenosis After Drug-Eluting Stent Implantation in a Patient with Polycythemia Vera: A Case Report

Journal of Agromedicine and Medical Sciences (AMS), 2023
Polycythemia vera happened in people around 40-60 years old and mostly men. The criteria are total red blood cells ≥36 mL/kg in males, thrombocytosis, leukocytosis, and JAK2 mutation.
I Gusti Ayu Ratna Dewi, Tristi Lukita Wening, Sidhi Laksono Purwowiyoto   +2 more
doaj   +1 more source

Muramidase in Polycythemia Vera [PDF]

Blood, 1970
Abstract The serum muramidase levels of 45 patients with polycythemia vera were found to be significantly elevated above the values in 20 normal subjects. The patients with polycythemia vera who were studied included those with active disease, those controlled with myelosuppressive agents and those in the spent phase.
Richard A. Binder, Richard A. Binder, Harriet S. Gilbert   +2 more
openaire   +3 more sources

Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management

American journal of hematology/oncology, 2020
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding ...
A. Tefferi, T. Barbui
semanticscholar   +1 more source

Aberrant expression of microRNA in polycythemia vera

Haematologica, 2008
Background Polycythemia vera is a clonal hematopoietic stem cell disorder in which the JAK2 V617F mutation is observed in >95% of patients, but an as yet unidentified process appears to initiate the clonal expansion of hematopoiesis.
Hana Bruchova, Michaela Merkerova, Josef T. Prchal   +2 more
doaj   +1 more source

Anesthetic management of a patient with polycythemia vera undergoing emergency repair of a type-A aortic dissection and concomitant coronary artery bypass grafting: a case report [PDF]

Korean Journal of Anesthesiology, 2015
Polycythemia vera is a chronic progressive myeloproliferative disease characterized by increased circulating red blood cells, and the hyperviscosity of the blood can lead to an increased risk of arterial thrombosis.
Hyeongwoo Im, Jeong Jin Min, Jaeyoung Yang, Sangmin Maria Lee, Jong Hwan Lee   +4 more
doaj   +1 more source

Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera

Haematologica, 2011
TET2 mutations are found in polycythemia vera and it was initially reported that there is a greater TET2 mutational burden than JAK2V617F in polycythemia vera stem cells and that TET2 mutations precede JAK2V617F.
Sabina I. Swierczek, Donghoon Yoon, Christine Bellanné-Chantelot, Soo Jin Kim, Cécile Saint-Martin, Francois Delhommeau, Albert Najman, Josef T. Prchal   +7 more
doaj   +1 more source

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

Haematologica, 2008
We analyzed the effect of hydroxyurea on the JAK2V617F allelic ratio (%JAK2V617F), measured in purified blood granulocytes, of patients with polycythemia vera and essential thrombocythemia.
François Girodon, Céline Schaeffer, Cédric Cleyrat, Morgane Mounier, Ingrid Lafont, Frédéric Dos Santos, Aurélie Vidal, Marc Maynadié, Sylvie Hermouet   +8 more
doaj   +1 more source

Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia

Haematologica, 2013
Subclones homozygous for JAK2V617F are more common and larger in patients with polycythemia vera compared to essential thrombocythemia, but their role in determining phenotype remains unclear.
Anna L. Godfrey, Edwin Chen, Francesca Pagano, Yvonne Silber, Peter J. Campbell, Anthony R. Green   +5 more
doaj   +1 more source

All we know about polycythemia vera: literature review and own experience

Онкогематология, 2015
The literature review and own long-term polycythemia vera diagnosis and treatment experience are presented in this article. The results of newest advances in pathogenesis description, modern diagnostic techniques and treatment modalities in polycythemia ...
K. M. Abdulkadyrov, V. A. Shuvaev, I. S. Martynkevich   +2 more
doaj   +1 more source